All In Biotech

Free tool

FAERS Monitor: Hepcludex

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761468 or its brand name (Hepcludex, Bulevirtide-Gmod). Reports on generic versions are filed under their own applications.

Reports

96

Serious

86

90% of reports

Hospitalization

25

Death reported

3

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • hepatic cirrhosis14
  • pancytopenia10
  • asthenia7
  • drug ineffective7
  • hepatitis d6
  • virologic failure6
  • fatigue5
  • hepatic failure5
  • hepatic fibrosis5
  • thrombocytopenia5
  • treatment noncompliance5
  • drug-induced liver injury4
  • hepatocellular carcinoma4
  • lichen planus4
  • off label use4

Reports by year received

View as table
YearReports
20203
202111
202217
202312
20249
20259
202635

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,063 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
hepatitis dSignal616870.27535.678,969
lichen planusSignal4378.6144.91,151
hepatic fibrosisSignal5319.7136.11,284
virologic failureSignal6244.7112.71,222
hepatic cirrhosisSignal14163.4100.72,101
hepatocellular carcinomaSignal4115.344.2346
pancytopeniaSignal1039.221.8336
hepatic failureSignal536.315.5138
drug-induced liver injurySignal427.910.779
treatment noncomplianceSignal520.08.573
thrombocytopeniaSignal59.84.231
astheniaSignal74.12.014
fatigue51.40.60
drug ineffective71.20.60
off label use41.00.40

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.